Analysis of 45 candidate genes for disease modifying activity in multiple sclerosis

被引:0
|
作者
S. V. Ramagopalan
G. C. DeLuca
K. M. Morrison
B. M. Herrera
D. A. Dyment
M. R. Lincoln
S.-M. Orton
M. J. Chao
A. Degenhardt
M. Pugliatti
A. D. Sadovnick
S. Sotgiu
G. C. Ebers
机构
[1] Level 3,Dept. of Clinical Neurology, University of Oxford
[2] West Wing,Wellcome Trust Centre for Human Genetics
[3] John Radcliffe Hospital,Dept. of Medical Genetics and Faculty of Medicine
[4] University of Oxford,Institute of Clinical Neurology
[5] Division of Neurology,undefined
[6] University of British Columbia,undefined
[7] University of Sassari,undefined
来源
Journal of Neurology | 2008年 / 255卷
关键词
multiple sclerosis; genetics; outcome;
D O I
暂无
中图分类号
学科分类号
摘要
Multiple sclerosis (MS) is a common inflammatory disease of the central nervous system unsurpassed for its variability in disease outcome. As little is conclusively known about MS disease mechanisms, we have selected a variety of candidate genes that may influence the prognosis of the disease based on their function. A cohort of sporadic MS cases, taken from opposite extremes of the putative distribution of long-term outcome using the most stringent clinical criteria to date, was used to determine the role of on MS disease severity. The MS cases selected represent the prognostic best 5 % (benign MS) and worst 5 % (malignant MS) of cases in terms of clinical outcome assessed by the EDSS. Genotyping the two sets of MS patients (112 benign and 51 malignant) and a replication cohort from Sardinia provided no evidence to suggest that the genes selected have any outcome modifying activity, although small effects of these genes cannot be ruled out.
引用
收藏
相关论文
共 50 条
  • [31] Genetic analysis of candidate genes modifying the age-at-onset in Huntington’s disease
    Silke Metzger
    Peter Bauer
    Jürgen Tomiuk
    Franco Laccone
    Stefano DiDonato
    Cinzia Gellera
    Caterina Mariotti
    Herwig W. Lange
    Helga Weirich-Schwaiger
    Gregor K. Wenning
    Klaus Seppi
    Bela Melegh
    Viktoria Havasi
    Laszlo Balikó
    Stefan Wieczorek
    Jacek Zaremba
    Dorota Hoffman-Zacharska
    Anna Sulek
    A. Nazli Basak
    Esra Soydan
    Jana Zidovska
    Vera Kebrdlova
    Massimo Pandolfo
    Pascale Ribaï
    Ludovit Kadasi
    Marta Kvasnicova
    Bernhard H. F. Weber
    Friedmar Kreuz
    Matthias Dose
    Manfred Stuhrmann
    Olaf Riess
    Human Genetics, 2006, 120 : 285 - 292
  • [32] Genetic analysis of candidate genes modifying the age-at-onset in Huntington's disease
    Metzger, Silke
    Bauer, Peter
    Tomiuk, Juergen
    Laccone, Franco
    DiDonato, Stefano
    Gellera, Cinzia
    Mariotti, Caterina
    Lange, Herwig W.
    Weirich-Schwaiger, Helga
    Wenning, Gregor K.
    Seppi, Klaus
    Melegh, Bela
    Havasi, Viktoria
    Baliko, Laszlo
    Wieczorek, Stefan
    Zaremba, Jacek
    Hoffman-Zacharska, Dorota
    Sulek, Anna
    Basak, A. Nazli
    Soydan, Esra
    Zidovska, Jana
    Kebrdlova, Vera
    Pandolfo, Massimo
    Ribai, Pascale
    Kadasi, Ludovit
    Kvasnicova, Marta
    Weber, Bernhard H. F.
    Kreuz, Friedmar
    Dose, Matthias
    Stuhrmann, Manfred
    Riess, Olaf
    HUMAN GENETICS, 2006, 120 (02) : 285 - 292
  • [33] Age as a predictive factor of disease activity after discontinuation of Disease Modifying Treatment in Multiple Sclerosis
    Soares, Mafalda Delgado
    Faustino, Patricia
    Sequeira, Joao
    Marques, Jose Pinto
    Sousa, Ana
    Grine, Teresa
    Mateus, Claudia
    Encarnacao, Susana
    Santos, Ana Catarina
    Gama, Anabela
    Capela, Carlos
    Ladeira, Filipa
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 970 - 971
  • [35] Comment on: "Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis"
    Tsivgoulis, Georgios
    Palaiodimou, Lina
    Katsanos, Aristeidis H.
    Voumvourakis, Konstantinos
    Hadjigeorgiou, Georgios M.
    Heliopoulos, Ioannis
    Karapanayiotides, Theodore
    Papathanasopoulos, Panagiotis
    Kilidireas, Constantinos
    Grigoriadis, Nikolaos
    CNS DRUGS, 2019, 33 (03) : 293 - 295
  • [36] Correction to: Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis
    Dimitrios Papadopoulos
    Dimos-Dimitrios D. Mitsikostas
    CNS Drugs, 2019, 33 : 93 - 97
  • [37] Comment on: “Oral Disease-Modifying Treatments for Relapsing Multiple Sclerosis: A Likelihood to Achieve No Evidence of Disease Activity or Harm Analysis”
    Georgios Tsivgoulis
    Lina Palaiodimou
    Aristeidis H. Katsanos
    Konstantinos Voumvourakis
    Georgios M. Hadjigeorgiou
    Ioannis Heliopoulos
    Theodore Karapanayiotides
    Panagiotis Papathanasopoulos
    Constantinos Kilidireas
    Nikolaos Grigoriadis
    CNS Drugs, 2019, 33 : 293 - 295
  • [38] Analysis of completeness for spontaneous reporting of disease-modifying therapies in multiple sclerosis
    Araujo, Ariane G. S.
    Lucchetta, Rosa C.
    Tonin, Fernanda S.
    Pontarolo, Roberto
    Borba, Helena H. L.
    Wiens, Astrid
    EXPERT OPINION ON DRUG SAFETY, 2021, 20 (06) : 735 - 740
  • [39] PRICE ANALYSIS OF MULTIPLE SCLEROSIS DISEASE-MODIFYING THERAPIES MARKETED IN THE US
    Bin Sawad, A.
    Seoane-Vazquez, E.
    Rodriguez-Monguio, R.
    VALUE IN HEALTH, 2015, 18 (03) : A282 - A282
  • [40] Analysis of multiple candidate genes in association with phenotypes of multiple sclerosis (vol 16, pg 652, 2010)
    Sombekke, M. H.
    Arteta, D.
    van de Wiel, M. A.
    Crusius, J. B. A.
    Tejedor, D.
    Killestein, J.
    Martinez, A.
    MULTIPLE SCLEROSIS JOURNAL, 2010, 16 (06) : 765 - 765